Phacoemulsification (Cataract Surgery) — Procedure, IOL Types & Recovery Guide — Cost, Top Hospitals & Success Rates | MyMedicPlus

Phacoemulsification (colloquially "phaco") is the gold-standard surgical technique for cataract extraction, performed through a 2.2–2.8 mm self-sealing microincision in the clear cornea. Ultrasonic energy delivered at approximately 40 kHz — alternating longitudinal and torsional vibration depending on machine settings — fragments the opaque crystalline lens into small emulsified pieces. These fragments are simultaneously aspirated by a coaxial irrigation-aspiration (I/A) system, maintaining anterior chamber stability throughout the procedure. An artificial intraocular lens (IOL) is then folded and injected through the same microincision into the empty capsular bag, restoring optical clarity without sutures.

Cataract — progressive opacification of the crystalline lens — is the leading cause of correctable blindness worldwide, responsible for approximately 51% of global blindness and affecting an estimated 65–95 million people. Nuclear sclerotic cataract from oxidative damage to lens crystallins predominates in older adults; posterior subcapsular cataracts are associated with systemic corticosteroid use, diabetes mellitus, and ultraviolet-B radiation; cortical cataracts present with spoke-like lens opacities and marked glare.

Phacoemulsification was pioneered by Charles D. Kelman in 1967 at a time when cataract surgery required a 10–12 mm incision, prolonged hospital admission, and 8 weeks of recovery with sand bags on the head. Modern techniques have reduced this to an outpatient 15–25 minute procedure performed under topical or local anaesthesia. Over 25 million phacoemulsification operations are performed annually worldwide, making it the world's most commonly performed elective surgical procedure.

The procedure achieves visual acuity of 6/12 or better in >95% of uncomplicated cases and provides immediate visual rehabilitation — most patients notice meaningful improvement within 24–48 hours of surgery. The evolution of IOL technology, from simple monofocal to premium toric, multifocal, and extended depth-of-focus (EDOF) designs, has progressively expanded patients' options for spectacle independence.

Cataract is classified by the anatomical location of lens opacification, aetiology, and degree of maturity. Each type influences surgical approach and difficulty.

Types by Location:

• Nuclear sclerosis: Hardening and yellowing of the lens nucleus from protein crosslinking; the most common type in adults over 60. Graded on the Lens Opacities Classification System (LOCS III) from Grade 1 (trace nuclear opalescence) to Grade 6 (brown/black dense nucleus). Dense nuclear cataracts ("black cataracts") require higher phacoemulsification energy and greater surgical skill.
• Cortical cataract: Wedge-shaped spoke-like opacities extending from the lens equator; cause glare and halos; easier to manage surgically as the nucleus is often softer.
• Posterior subcapsular cataract (PSC): Located immediately anterior to the posterior capsule; causes particularly severe glare and near-vision blur disproportionate to slit-lamp findings; associated with corticosteroid use, diabetes, high myopia, and posterior segment disease. Technically challenging — thin posterior capsule directly behind the opacity increases PCR risk.
• Anterior subcapsular: Directly behind the anterior capsule; may interfere with capsulorhexis if dense.

Types by Aetiology:

• Age-related (senile): By far the most common; universal occurrence with ageing; onset typically after 55 years
• Diabetic ("snowflake" cataract): Bilateral cortical or PSC; osmotic mechanism from glucose-sorbitol accumulation; may present at younger ages in poorly controlled T2DM
• Steroid-induced: PSC pattern; dose- and duration-dependent with systemic, topical, inhaled, and peri-ocular steroids
• Traumatic: Rosette-shaped cortical opacity (contusion); or mature opacification after penetrating injury
• Congenital: Present at birth; visually significant congenital cataract requires urgent surgery to prevent deprivation amblyopia in the sensitive period; diffuse, lamellar, anterior polar, posterior polar, and nuclear subtypes
• Secondary (complicated): Following prolonged uveitis, retinitis pigmentosa, high myopia, or systemic diseases

Maturity Classification:

• Immature: partially opaque lens with visible red reflex on retroillumination — most surgically favourable
• Mature: completely opaque lens, absent red reflex — anterior capsule staining with trypan blue dye is essential to enable capsulorhexis visualisation
• Hypermature/Morgagnian: liquefied cortex with sunken nucleus — highest risk of capsule complications

The decision to proceed with phacoemulsification is based on both objective visual acuity and functional impact on the patient's daily life. The threshold is not a fixed VA measurement but a contextual clinical judgement.

Surgical Indications:

• Best-corrected visual acuity (BCVA) of 6/12 (20/40) or worse in the affected eye — the threshold for driving in most countries; the minimum for NHS England eligibility
• Better VA but functionally significant impact on driving, occupation, hobbies (e.g., reading, playing music), or significant glare disability affecting safety
• Visually significant cataract in any eye that is the only eye, or the better-seeing eye
• Dense PSC causing near-vision impairment despite good distance VA (a common scenario)
• Medical indications: cataract causing secondary angle-closure glaucoma (phacomorphic or phacolytic); lens-induced uveitis; need to visualise the retina for posterior segment assessment and treatment (e.g., diabetic retinopathy requiring laser or anti-VEGF)
• Congenital cataract: urgent surgery within weeks of diagnosis if visually significant to prevent deprivation amblyopia

Pre-operative Assessment:

• Best-corrected visual acuity: Establishing pre-operative baseline; checking that visual loss is attributable to cataract rather than co-existing macular disease
• Slit-lamp assessment: Cataract grading (LOCS III); anterior chamber depth; zonular integrity (phacodonesis — lens tremulousness with eye movement indicates loose zonules, increased surgical risk); pupil dilation response (small pupils from pseudoexfoliation, previous surgery, tamsulosin — pupil expansion rings or hooks planned pre-operatively)
• Biometry (IOL power calculation): IOL Master 700 or Lenstar (optical coherence biometry) measure axial length, keratometry, anterior chamber depth, lens thickness, and white-to-white diameter. Barrett Universal II formula is the most accurate formula across all axial lengths (proven superior to SRK/T, Hoffer Q, Holladay I, and II in multiple comparative studies including the EUREQUAL study). For post-refractive surgery corneas, the Holladay II with Pentacam corneal measurements or Barrett True-K formula is preferred.
• Keratometry and topography: Corneal astigmatism measurement for toric IOL selection; Pentacam Scheimpflug imaging to exclude corneal irregularity or early keratoconus (contraindication to toric IOL)
• Macular OCT: Essential before premium IOL (multifocal/EDOF) implantation — epiretinal membrane, macular hole, or AMD may reduce the visual quality benefit of premium IOL; patient counselled on realistic expectations
• Medical history and medications: Alpha-1 antagonists (tamsulosin, alfuzosin, silodosin — for benign prostatic hyperplasia and sometimes prescribed for kidney stones) cause intraoperative floppy iris syndrome (IFIS); require pre-operative planning with iris hooks or phenylephrine-lidocaine drops. Anticoagulants (warfarin, DOACs) are not routinely stopped for topical-only anaesthesia phaco.

Modern phacoemulsification is a sequence of precise microsurgical steps, each requiring mastery to minimise complication risk:

Surgical Technique — Step by Step:

• Anaesthesia: Topical (proxymetacaine or tetracaine drops) with or without intracameral lignocaine 1% — the standard for most elective cases. Subtenon block for higher-risk cases or patient anxiety. Peribulbar or retrobulbar block for complex or prolonged surgery.
• Incision: A 2.2–2.8 mm clear corneal incision (CCI) is made at the steepest corneal meridian (or temporally) using a calibrated keratome. A 1.0–1.5 mm paracentesis port is created at 90° for the second instrument. The CCI is self-sealing by internal flap architecture — sutures are rarely required. Smaller incisions (2.2 mm) reduce surgically induced astigmatism (SIA) and are preferred for toric IOL precision.
• Continuous Curvilinear Capsulorhexis (CCC): A circular tear of the anterior lens capsule of precisely 5.0–5.5 mm diameter, performed with a bent needle (cystotome) or Utrata forceps in a methylcellulose or viscoelastic-filled chamber. A CCC of correct size is critical: too large risks posterior capsule rupture; too small (phimosis) contracts onto the optic edge. Trypan blue vital dye is essential for visualisation in mature cataracts with absent red reflex.
• Hydrodissection and Hydrodelineation: Balanced salt solution (BSS) injected under the anterior capsular edge separates the cortex from the capsule (hydrodissection — facilitates cortical clean-up) and separates the epinucleus from the endonucleus (hydrodelineation — for nuclear sculpting). The "golden ring" sign at hydrodelineation confirms successful separation.
• Phacoemulsification — Nuclear Disassembly Techniques:
  — Divide-and-conquer: The nucleus is grooved in 2–4 axes and fractured into quadrants; classical learning technique; most versatile for moderate nuclear density
  — Stop-and-chop: A single deep groove is made, then the nucleus is impaled with the phaco tip and chopped tangentially with a second chopper; faster; less ultrasound energy needed
  — Phaco-chop: No groove; the phaco tip impales the nucleus directly and a chopper is passed to the equator to chop the lens; fastest technique; least energy; most energy-efficient for dense nuclei
  The key metrics are cumulative dispersed energy (CDE) and effective phaco time (EPT) — minimised by efficient nuclear technique to reduce corneal endothelial cell loss.
• Irrigation-Aspiration (I/A): After nucleus removal, residual cortical lens material is aspirated from the capsular bag using a bimanual or coaxial I/A handpiece. Complete cortical clean-up is essential to prevent posterior capsule opacification and improve IOL centration.
• IOL Implantation: The capsular bag is inflated with viscoelastic; the IOL (folded or rolled) is injected through a cartridge through the 2.2–2.8 mm incision. The haptics unfold within the bag; precise IOL positioning in the bag ensures optimal centration and IOL power calculation accuracy. Viscoelastic is then fully removed to prevent IOP spike.

IOL Selection — Types and Indications:

• Monofocal IOL: Single focus at one distance (usually distance); patient requires reading glasses for near work. Spherical and aspheric designs; aspheric preferred to reduce positive spherical aberration. Suitable for all patients; funded by NHS/Medicare as standard.
• Toric IOL: Monofocal IOL with built-in cylindrical correction for pre-existing corneal astigmatism (>0.75 D). Corrects astigmatism that cannot be addressed by limbal relaxing incisions. Requires precise axis marking (ORA system intraoperative aberrometry or ink marking) and stable zonular support. AcrySof Toric, TECNIS Toric, AT TORBI are established platforms.
• Multifocal IOL: Multiple focal points enabling both distance and near vision without spectacles; uses diffractive rings on the lens optic (ReSTOR, PanOptix, TECNIS Multifocal). Trade-offs: reduced contrast sensitivity, halos and starbursts at night (15–25% experience troublesome symptoms, with 1–3% requesting explantation). Contraindicated in patients with AMD, macular pathology, or moderate-severe amblyopia.
• Extended Depth-of-Focus (EDOF) IOL: Single elongated focal zone providing good distance and intermediate vision, with less near focus than multifocals but significantly fewer photic phenomena. Examples: TECNIS Symfony, AcrySof IQ Vivity (non-diffractive wavefront-shaping design — fewer halos than diffractive EDOFs), PanOptix (technically a trifocal). The preferred premium IOL for most patients due to better neuroadaptation and lower dysphotopsia rates.
• Light-adjustable lens (LAL): RxSight's light-adjustable IOL allows post-operative refractive adjustment using UV light exposure (3 adjustments + lock-in) to fine-tune the spherical and cylinder power after wound healing — useful for post-refractive surgery eyes where biometry accuracy is reduced.

Femtosecond Laser-Assisted Cataract Surgery (FLACS): Femtosecond lasers (LenSx — Alcon, CATALYS — Johnson & Johnson, LensAR, VICTUS) can automate corneal incisions, capsulorhexis, and pre-fragmentation of the nucleus before phacoemulsification. FLACS produces more precise, circular capsulotomies than manual CCC and reduces phaco energy required. However, multiple randomised controlled trials (FEMCAT, ESCRS FLACS study, Wiggins et al.) have not demonstrated superior visual outcomes or lower complication rates compared to skilled manual phaco. FLACS adds $500–$1,500 per eye in cost. Its primary advantages are in complex cases (small pupils, dense cataracts, post-refractive surgery) and in teaching programmes.

Phacoemulsification with IOL implantation achieves excellent, reproducible visual outcomes and is among the highest-value surgical procedures in all of medicine — restoring functional vision, preventing blindness, and enabling independence.

Visual Acuity Outcomes:

• Best-corrected visual acuity (BCVA) of 6/12 or better: achieved in >95% of uncomplicated phacoemulsification cases
• BCVA of 6/6 (20/20) or better: achieved in approximately 75–80% of uncomplicated cases with modern IOL biometry
• Uncorrected visual acuity (UCVA) of 6/12 or better: achieved in 60–70% with monofocal IOL targeted to emmetropia; near 90% with premium IOL in optimally selected patients
• Visual improvement begins within 24–48 hours; full stabilisation and final spectacle prescription at 4–8 weeks post-operatively

IOL-Specific Outcomes:

• Toric IOL: Reduces residual cylinder by 70–80% compared to non-toric IOL in patients with >1.0 D pre-operative corneal astigmatism; significantly improved UCVA at distance without spectacles
• PanOptix (trifocal) IOL: 84% of patients achieve binocular UCVA of 20/20 or better at distance, 20/25 at intermediate, and 20/20 at near (Kohnen et al., Journal of Cataract and Refractive Surgery 2019); spectacle independence achieved in 85–95%
• TECNIS Symfony (EDOF): Comparable distance and intermediate VA to monofocal with significantly better near vision; halos reported in <10% at troublesome levels vs 20–30% with diffractive multifocals

Quality of Life Benefits:

• Restoration of driving ability (return to driving typically at 1–4 weeks after uncomplicated surgery)
• Significant reduction in falls risk in older adults: randomised trial (Harwood et al., Lancet 2005) demonstrated 34% reduction in falls at 12 months after first-eye cataract surgery in patients over 70
• Improvements in reading, face recognition, colour perception, and occupational function
• VFQ-25 (Visual Function Questionnaire) scores improve meaningfully in all subscales post-operatively; improvements equivalent in magnitude to coronary artery bypass surgery for angina

Refractive Accuracy:

• Barrett Universal II formula achieves prediction error within ±0.5 D in >80% of cases and within ±1.0 D in >95% — a substantial improvement over older generation formulae (SRK/T, Holladay I, Hoffer Q)
• Optical biometry (IOL Master 700, Lenstar) has replaced immersion A-scan ultrasound as the standard due to superior axial length accuracy and non-contact technique

Phacoemulsification at experienced surgeons is one of the safest surgical procedures performed, with intraoperative complication rates of <1% at high-volume centres. Patients must nonetheless be informed of all potential adverse outcomes before consenting.

Intraoperative Complications:

• Posterior capsule rupture (PCR): The most important intraoperative complication; occurs in 0.5–2% of routine cases (national UK audit: 1.92%, RCOphth National Ophthalmology Database 2023). Risk factors: dense nuclear cataract, posterior subcapsular morphology, pseudoexfoliation, small pupil, previous vitrectomy, high myopia. Management: anterior vitrectomy if vitreous presentation; in-the-bag or sulcus IOL placement depending on remaining capsular support. Increased risk of post-operative complications (CME, retinal detachment) compared to uncomplicated surgery.
• Zonular dialysis: Separation of zonular fibres supporting the lens capsule; leads to capsular instability; may require capsular tension ring (CTR) to stabilise the bag; risk highest with pseudoexfoliation syndrome, Marfan syndrome, trauma, and previous pars plana vitrectomy.
• Dropped nucleus: Rare but serious complication when nuclear fragment falls into the vitreous cavity through a PCR; requires planned pars plana vitrectomy (PPV) at the same sitting or electively; associated with higher rates of post-operative CME, elevated IOP, and corneal decompensation.
• Corneal wound burn: Very rare with modern pulsed and torsional phaco energy delivery; generates heat at incision if sleeve occlusion occurs with sustained energy delivery.

Early Post-operative Complications (<6 weeks):

• Endophthalmitis: Intraocular bacterial infection; incidence 0.02–0.08% in current series. Presents within 3–7 days with pain, severe visual loss, hypopyon, and lid oedema. A sight- and potentially life-threatening emergency. The landmark ESCRS prophylaxis study (2006) demonstrated that intracameral cefuroxime 1 mg in 0.1 mL BSS at the end of surgery reduced endophthalmitis incidence by 4.92× compared to topical drops alone. Intracameral cefuroxime is now standard of care across the EU and increasingly worldwide. Treatment: urgent vitreous tap and culture, intravitreal vancomycin + ceftazidime (or amikacin); PPV for severe cases.
• Cystoid macular oedema (CME, Irvine-Gass syndrome): 1–3% clinically significant incidence; presents at 4–8 weeks with reduced vision; diagnosed on OCT. Treated with topical NSAIDs (nepafenac, ketorolac) and steroids; resolves in >90% with treatment; chronic CME (>6 months) requires intravitreal steroid or anti-VEGF.
• IOP elevation: Transient IOP spike immediately post-operatively from retained viscoelastic; treated with topical or oral antihypertensives if sustained.
• Corneal oedema (Descemet's folds): Transient in most cases; clears as corneal endothelial pump function recovers. Permanent decompensation in patients with pre-existing low endothelial cell count (Fuchs endothelial dystrophy) or excessive phaco energy.

Late Post-operative Complications (>6 weeks):

• Posterior Capsule Opacification (PCO): The most common late complication; occurs in 20–40% of patients at 2 years from residual lens epithelial cell (LEC) migration and proliferation on the posterior capsule. Symptoms: gradual visual blurring and glare, identical to recurrence of original cataract. Treatment: outpatient YAG (Nd:YAG) laser capsulotomy — a 5-minute procedure creating a central aperture in the opacified posterior capsule; immediate vision restoration; no anaesthesia or recovery required. PCO rate is significantly reduced by sharp-edged hydrophobic acrylic IOL designs (AcrySof platform), which create a mechanical barrier to LEC migration.
• IOL dislocation/decentration: Late in-the-bag IOL/capsular complex dislocation; associated with pseudoexfoliation syndrome and progressive zonular laxity; requires IOL re-positioning (pars plana vitrectomy with suture fixation of IOL to sclera or iris) in symptomatic cases.
• Retinal detachment: Small but real increase in lifetime retinal detachment risk after cataract surgery, particularly in high myopes (axial length >26 mm) — lifetime risk approximately 1–2% vs 0.1% in the general population. Risk highest in first 6 months post-operatively and in the setting of PCR.
• Dysphotopsia: Positive dysphotopsia — halos and starbursts, more common with multifocal IOLs (20–30% report; 1–3% severe); usually improve with neuroadaptation at 3–12 months. Negative dysphotopsia — an unexplained dark temporal arc seen by some patients with monofocal IOLs; mechanism incompletely understood; resolves in most cases by 12 months.

Phacoemulsification is performed as a day-case procedure; most patients return home within 2–4 hours of surgery. Recovery is rapid, with functional vision typically restored within 1–2 days.

Immediate Post-operative Instructions:

• Protect the eye with a shield at night for the first 1–2 weeks
• Avoid rubbing the eye
• No swimming or exposure to potentially contaminated water for at least 2–4 weeks
• No heavy lifting or straining (Valsalva manoeuvre) for 2 weeks — increases risk of wound dehiscence and vitreous pressure change
• Contact sports avoided for 4 weeks; non-contact activities resumed as comfort allows
• Driving: may resume when VA in the operated eye meets the minimum standard (6/12 or better) and the patient is comfortable — typically 1–4 weeks post-operatively

Topical Medication Regimen:

• Topical antibiotic (chloramphenicol 0.5%, levofloxacin, or moxifloxacin): 4 times daily for 1 week
• Topical steroid (prednisolone 1%, dexamethasone 0.1%, or difluprednate 0.05%): 4 times daily tapering over 4 weeks; maintains anti-inflammatory effect and reduces CME risk
• Topical NSAID (nepafenac 0.1% or ketorolac 0.5%): commenced pre-operatively and continued for 4 weeks post-surgery in eyes at higher CME risk (diabetic patients, PSC cataract, previous uveitis, single-eye patients)
• Some surgeons use a single combined anti-inflammatory drop to simplify the regimen and improve adherence

Follow-up Schedule:

• Day 1: Anterior chamber assessment (wound integrity, chamber depth, signs of infection), IOP measurement, removal of eye pad/shield
• 1 week: IOP check, wound assessment, VA measurement, early complication screening; review in A&E or urgent clinic if pain, significant redness, or visual deterioration before this point
• 4–6 weeks: Final visual acuity; refraction for new spectacle prescription when corneal wound healing is complete and refractive stability achieved; OCT macula if VA not as expected

YAG Capsulotomy for PCO:

• Outpatient day-case laser procedure; no incisions, injections, or recovery
• A contact lens is placed on the eye after topical anaesthetic drop; Nd:YAG laser (1064 nm) is focused on the posterior capsule and a central circular aperture created with multiple pulses
• Vision improvement typically noted within 24 hours
• IOP check at 1 hour post-YAG and 1 week follow-up to detect IOP spike or very rare late complications (posterior vitreous detachment, cystoid macular oedema, very rarely retinal detachment — risk increased in high myopes, require counselling)

Second Eye Surgery:

• Second-eye surgery is typically planned 2–6 weeks after the first eye — once first-eye recovery is confirmed and biometric data from the first eye informs any adjustments to the IOL power selection for the second eye (the "surgeon factor optimisation")
• Binocular visual function substantially improves after second-eye surgery; stereopsis is restored and spectacle dependence further reduced

Cataract surgery is one of the most widely performed funded operations in the world, covered by most national health systems and insurance plans for functionally significant disease. Private costs vary enormously by country, IOL choice, and technology used.

Factors Influencing Cost:

• IOL type: The single most important cost variable. Monofocal IOL is covered as standard by NHS England, Medicare (US), and most national health plans. Premium IOLs (toric, multifocal, EDOF, light-adjustable) are patient-funded upgrades — typically adding £500–£2,500 (UK) or $1,000–$3,000 (US) per eye on top of the funded procedure.
• FLACS (femtosecond laser-assisted surgery): Adds $500–$1,500 per eye; not covered by NHS or standard Medicare; self-funded by patients wishing the additional capsulotomy precision
• Anaesthetic method: Topical anaesthesia (drops only) adds no anaesthetic fee beyond standard nursing; peribulbar or general anaesthesia increases cost and may require additional medical consultation
• Surgeon experience and reputation: Complex cases (dense cataract, pseudoexfoliation, post-refractive surgery corneas, single eye) command higher surgeon fees
• Pre-operative investigations: Biometry, keratometry, Pentacam topography, macular OCT — especially relevant for premium IOL selection; $200–$600 additional pre-operative workup
• Intraoperative technology: ORA intraoperative aberrometry for real-time IOL power verification (particularly for post-refractive surgery eyes); CALLISTO digital marking for toric axis alignment — adds $500–$800 per eye at US private centres
• Post-operative YAG capsulotomy: NHS-funded in the UK; $500–$1,500 in US private practice when required

Approximate Costs by Country (2025, Private Rates):

• United States (uninsured): $3,000–$6,000 per eye (monofocal); $5,000–$9,000 per eye (premium IOL including FLACS)
• United Kingdom (private, monofocal): £1,500–£3,000 per eye; £2,500–£4,500 per eye (premium IOL)
• NHS England: fully funded for patients meeting clinical criteria (VA ≤6/12 or equivalent functional impairment); no patient cost for standard monofocal IOL
• India (JCI/NABH-accredited centre): $300–$800 per eye (monofocal); $700–$2,500 per eye (premium); $1,200–$3,500 (FLACS with premium IOL)
• Thailand: $800–$2,000 per eye; Singapore: $2,000–$4,500; Turkey: $500–$1,500

Medical Tourism Considerations: India, Thailand, and Turkey are the most popular medical tourism destinations for cataract surgery, offering 60–80% cost savings versus US or UK private rates at internationally accredited centres. Patients should verify that the clinic uses established IOL platforms (Alcon AcrySof, Johnson & Johnson TECNIS, Bausch & Lomb enVista), employs a trained cataract surgeon with verifiable case volume (>500 cases/year), and has A-scan biometry plus optical coherence biometry available. Post-operative follow-up with a local ophthalmologist at home is essential.

For most patients with visually significant cataract, phacoemulsification is the gold-standard treatment with no equivalent alternative that achieves comparable outcomes. However, alternatives to immediate surgery or to the standard technique are relevant in specific circumstances.

Watchful Monitoring (Non-surgical):

• Appropriate for patients with early-to-moderate cataract where vision remains adequate for their daily needs (>6/9 with glasses, no functional impairment)
• Annual or biannual ophthalmology review with VA documentation and slit-lamp grading
• Updated spectacle prescription and strong reading lighting can compensate for mild nuclear sclerosis for several years
• Anti-cataract eye drops: N-acetylcarnosine (Can-C drops) and other antioxidant formulations are marketed but have no robust evidence of efficacy in halting or reversing human cataract from peer-reviewed randomised trials; not recommended by any national ophthalmology organisation

Manual Small-Incision Cataract Surgery (MSICS):

• An alternative technique using a 5–8 mm scleral tunnel incision through which the nucleus is expressed whole (extracapsular cataract extraction, ECCE) or manually fragmented
• Requires no phacoemulsification machine — significantly lower equipment cost; applicable for dense/hypermature cataracts where phaco energy requirements would be very high
• Equivalent visual outcomes to phaco in experienced hands (Cochrane review, Ang et al.); higher surgically induced astigmatism from larger incision; longer recovery
• Most commonly used in resource-limited settings (sub-Saharan Africa, parts of South Asia); responsible for approximately 80% of cataract operations globally by volume

Conventional (Large-Incision) Extracapsular Cataract Extraction (ECCE):

• 10–12 mm incision with manual nucleus delivery and cortical aspiration; now largely obsolete in high-resource settings due to higher astigmatism, suture-related complications, and longer rehabilitation compared to phaco
• Still appropriate as a rescue conversion procedure when severe intraoperative complications preclude completion of phacoemulsification

Femtosecond Laser-Assisted Cataract Surgery (FLACS) as an Alternative to Manual Phaco:

• FLACS automates incisions, capsulorhexis, and nuclear pre-fragmentation; marketed as reducing the "human error" component of these steps
• Multiple RCTs have not demonstrated superiority of FLACS over expert manual phacoemulsification for visual outcomes or overall complication rates, but FLACS provides more precise, reproducible capsulotomies and reduces cumulative phaco energy required — potentially beneficial in eyes with Fuchs endothelial dystrophy or borderline endothelial cell counts

Refractive Lens Exchange (RLE) for Presbyopia:

• In patients over 50 with clear lenses (no cataract) who wish to reduce spectacle dependence — particularly high hypermetropes — the natural lens is electively removed and replaced with a premium IOL
• The surgery is identical to phacoemulsification; the "lens" removed is clear rather than opaque
• Eliminates future cataract development (the natural lens cannot opacify once removed); highly effective for spectacle independence with premium IOL
• Not eligible for NHS or Medicare funding (elective refractive procedure); self-funded at $5,000–$12,000 per eye bilaterally